

Enoxaparin – Transition to biosimilar Inhixa®

The Isle of Wight NHS Trust has been using the biosimilar enoxaparin product, Inhixa®, for all new low-molecular weight heparin initiations for the last 18-months.

The local and mainland Trusts have switched to the Inhixa® brand for enoxaparin to be assured of consistent stock availability.

MHRA advice is that biological medicine (including biosimilars) should be prescribed by brand name and supports pharmacovigilance and continuity of supply for the patient.

To support patient safety by ensuring that patients consistently receive the same brand of enoxaparin the Isle of Wight CCG are recommending that practices use Inhixa® brand for all new initiations and switch patients currently using Clexane® (or generic Enoxaparin) to Inhixa®. This clinical advice has been approved by PCPC and IMOC.

As patients need to be informed in person about the change of brand, and the second click (bullet point 9 on the patient information leaflet) required to activate the protective needle cover, the MOT will not be switching patients remotely.

Important information regarding the switch to Inhixa®:

- Please prescribe **Inhixa® by brand name** - *and NOT Enoxaparin*
- Inhixa® has a different mechanism for activating the needle guard – *double click required*
- Inhixa® has important differences in both colour coding and concentration to the originator Clexane®
- It is therefore important that the patient receives the brand that they have been initiated on and been given training on
- Please reduce the confusion for your patient, by giving the drug intended. Check which brand the patient has been prescribed for safety & continuity of care.
- Community Pharmacists should check any prescriptions for generic Enoxaparin to confirm which brand the patient had previously or was discharged from hospital with.

Resources

- **Further training, resources, leaflets and dummy pens to support the use of Inhixa® :**
Please contact Angela Willcocks (angela.willcocks@uk.techdow.com / 07949 812432).
- **Inhixa® website:** www.techdow-pharma.co.uk
- **Full SMPC details:**
<https://www.medicines.org.uk/emc/company/3367/Techdow%20Pharma%20Ltd>
- **Supply Chain Enquiries:** supplychain@uk.techdow.com
- **Please click on the link to a video that demonstrates how Inhixa® is administered:**
<http://www.techdow-pharma.co.uk/productsInfo/>

For more information or advice, please contact the Isle of Wight CCG Medicines Optimisation Team on iwccg.mot@nhs.net.

Thank you.